Tag Archive | "industry analysis"

Market research analysis: Monoclonal antibody partnering

Tags: , , ,

A recent market research analysis of monoclonal antibody partnering has shown a high interest in partnering deals involving monoclonal antibody technology in the past few years Read the full story

Diagnostics partnering: recent life science trends 2009-2014

Tags: , , ,

Diagnostics are subject to numerous partnering deals every year. Here we provide a review of recent life science trends in deal making activity Read the full story

Trends analysis: Cancer vaccine partnering on the rise

Tags: , , ,

Recent trends analysis suggests that research in personalized medicine and vaccine development for disease treatment has increased partnering and collaboration in this arena.  Read the full story

Industry trends in infectious vaccines dealmaking – 2009 to 2014

Tags: , , , ,

Industry trends suggest that infectious vaccines research and development is an increasingly active component of healthcare business development. The last decade has witnessed a significant number of infectious vaccines partnering and M&A activity Read the full story

Industry analysis in drug delivery partnering activity


Industry analysis reveals that over 2000 drug delivery partnering deals have been announced between January 2009 and April 2014, showing that drug delivery partnering is in good health, with numerous big pharma and big biotech companies actively partnering delivery technologies to support development of targeted therapeutics Read the full story

Industry ananlysis: AstraZeneca should consider merger of equals with US group AbbVie

Tags: , , , , ,

Industry analysis suggest that AstraZeneca could consider a merger of equal deal with AbbVie which  would give $4bn of synergies, but also suggests five point plan for future growth Read the full story

Industry analysis: Merck’s Frazier Says He Won’t Follow Pfizer in Splitting Company

Tags: , , , , ,

Merck & Co Chief Executive Officer Ken Frazier said he doesn’t plan on breaking up the company by splitting off businesses the way Pfizer and Abbott Laboratories are doing, as reported by industry analysis experts Read the full story